Vimta Labs Share Price

Healthcare Services company Vimta Labs announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Total Income: Stood at Rs 1,120 million in Q4FY26, representing a growth of 11.5% QoQ from Rs 1,005 million in Q3FY26 and a 16.6% YoY increase from Rs 961 million in Q4FY25. EBITDA (including other income): Reached Rs 421 million, an increase of 22.3% QoQ from Rs 344 million and 21.5% YoY from Rs 347 million. EBITDA Margin: Improved to 37.6% in Q4FY26, compared to 34.3% in Q3FY26 and 36.1% in Q4FY25. Profit Before Tax (PBT): For continuing operations, PBT was Rs 290.47 million in Q4FY26, compared to Rs 250.27 million in Q4FY25. Profit After Tax (PAT): For continued operations, PAT stood at Rs 211 million, up 20.1% QoQ from Rs 176 million and 15.2% YoY from Rs 183 million. PAT Margin: Reported at 18.9% for the quarter. Basic EPS: Stood at Rs 4.7 for Q4FY26. FY26 Financial Highlights: Total Income: Reached Rs 4,163 million for the full year, a growth of 19.5% YoY from Rs 3,482 million in FY25. EBITDA: Reported at Rs 1,489 million, up 18.0% YoY from Rs 1,262 million in FY25. EBITDA Margin: Stood at 35.8% for the full year. Profit Before Tax (PBT): Including discontinued operations, PBT was Rs 1,039.53 million, compared to Rs 904.05 million in FY25. Profit After Tax (PAT): For continued operations, PAT reached Rs 775 million, marking a 16.1% YoY growth from Rs 668 million in FY25. PAT Margin: Stood at 18.6% for FY26. Basic EPS: Stood at Rs 17.4 for FY26. Business Highlights Segment Information: The company operates in only one reportable segment, namely "Contract Research and Testing Services". Growth Drivers: The strong annual performance was primarily driven by exceptional results in the Pharma and Food divisions. Dividend: The Board of Directors has recommended a final dividend of Rs 2 per share (100%) with a face value of Rs 2 each for the financial year 2025-26, subject to shareholder approval. International Expansion: The Board approved the proposal to incorporate a wholly owned subsidiary of the company in the USA. Bonus Issue: Following approval in June 2025, the company issued bonus shares in a 1:1 ratio, allotting 2,22,52,764 equity shares. Labour Code Impact: The company recognized a non-recurring incremental impact of past service cost in gratuity amounting to Rs 16.16 million due to new labour codes, which was recorded as an exceptional item in FY26. Executive Leadership: The Board approved the reappointment of Dr. S. P. Vasireddi as Executive Chairman for a five-year term effective from July 1, 2026. Divestment Note: The sale of the Diagnostic and Pathological services business to Thyrocare Technologies was completed in October 2024. The company continues to receive a Brand Royalty fee of 5% of the revenue from this business. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to close this fiscal year on a strong note, achieving the highest-ever quarterly revenue of Rs. 1,120 Mn, up by 11.5% YoY. On a full-year basis, we crossed an important milestone and achieved a revenue of Rs. 4,163 Mn. These strong results were driven by the exceptional performance of our Pharma, and Food divisions. Sustained demand across sectors for high-quality research and testing services, coupled with the continued trust and confidence demonstrated by our customers, enabled us to deliver a strong EBITDA margin for the year. This performance underscores the strength of our diversified service portfolio, operational discipline, and customer-centric approach. As we move forward, we remain focused on expanding capabilities, investing in technology and talent, and strengthening long-term partnerships to drive sustainable growth and value creation for all stakeholders.” Result PDF

• Trendlyne
• 1 month 1 week ago

Healthcare Services company Vimta Labs announced Q3FY26 results Revenue: Rs 986.33 million against Rs 899.23 million during Q3FY25, change 10%. PBT: Rs 249.87 million against Rs 239.16 million during Q3FY25, change 4%. PAT: Rs 175.86 million against Rs 175.16 million during Q3FY25, change 0%. EPS: 3.96 for Q3FY26. Result PDF

• Trendlyne
• 4 months 2 weeks ago

Healthcare Services company Vimta Labs announced Q2FY26 results Q2FY26 Financial Highlights: Total Income for Q2FY26 was at Rs 1,045 million EBITDA for Q2FY26 was Rs 369 million; EBITDA margin was at 35.3% PBT for Q2FY26 was at Rs 263 million Q2FY26 PAT was at Rs 199 million; PAT margin was at 19.1% Basic EPS in Q2FY26 was Rs 4.5 H1FY26 Financial Highlights: Total Income for H1FY26 was at Rs 2,038 million EBITDA for H1FY26 was Rs 723 million; EBITDA margin was at 35.5% PBT for H1FY26 was at Rs 515 million H1FY26 PAT was at Rs 388 million; PAT margin was at 19.0% Basic EPS in H1FY26 was Rs 8.7 Harita Vasireddi, Managing Director, Vimta Labs, said: "I am delighted to share that Vimta Labs had a successful quarter with highest ever revenue reported i.e. ~Rs 104 crore. This growth was a result of our Pharmaceutical research and testing services and Food testing services performing well, while experiencing stable performance from other services provided by us. We would like to mention that our company had a successful WHO audit for Clinical Research during the quarter, reflecting our commitment to maintain the highest global standards of quality and compliance. With a focus on maintaining excellence in quality, innovation, and competence, we continue to strengthen our capabilities and deliver sustainable value to all stakeholders.” Result PDF

• Trendlyne
• 7 months 1 week ago